The Benefit of Bermekimab in Patients With Systemic Sclerosis
Status:
Active, not recruiting
Trial end date:
2021-07-19
Target enrollment:
Participant gender:
Summary
This is a proof-of concept RCT trying to generate evidence that inhibition of IL-1α through
the administration of bermekimab may inhibit progression of SSc.